DM-Pharma, spol. s r.o.Active
Key figures
Key figures
2024Dividends
calculatedDistributed as dividends 203 373 € (100 % of distributable profit).
Balance sheet structure
Summary of annual reports2019–2024
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Revenue (net turnover) | 558 | 195 | 0 | 0 | 49 |
| Profit for the reporting year | -34 593 | -18 766 | -22 219 | -12 871 | -20 738 |
| Retained earnings of previous periods | 291 823 | 257 229 | 238 463 | 216 244 | 0 |
| Total assets | 306 932 | 287 188 | 264 968 | 252 104 | 231 264 |
| Total liabilities | 9 537 | 8 560 | 8 559 | 8 566 | 211 837 |
| Total equity | 297 395 | 278 628 | 256 409 | 243 538 | 19 427 |
| Calculated dividends | 0 | 0 | 0 | 0 | 203 373 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Similar companies
Summary: DM-Pharma, spol. s r.o.
Overview
DM-Pharma, spol. s r.o. (IČO 31370934) is a limited liability company (s.r.o.). The company was incorporated in 1994 and has existed for 32 years. Registered office according to the register: Bratislava. Main activity according to the Statistical Office: maloobchod s farmaceutickými výrobkami (SK NACE 4773).
People
The company has one statutory representative. According to the register, the company has 2 shareholders. The registered capital is 36 514 €.
Financial results
Revenue for 2024 was 49 €. From 2019 to 2024, revenue fell by an average of 82,1 % per year. 2024 ended with a loss of 20 738 €. The company was profitable in 1 of the 6 reported years. At the end of 2024 the company had total assets of 231 264 € and equity of 19 427 € (equity ratio 8,4 %).
Sources and freshness
Company and people data come from the Register of Legal Entities (Statistical Office SR, CC BY 4.0) and financial statements from the Register of Financial Statements (Ministry of Finance SR); icoprofil.sk updates them daily. Data as of 9. 11. 2026. Changes, averages and ratios are calculated by icoprofil.sk from open data and are not an official assessment.